Marlene Balys
Overview
Explore the profile of Marlene Balys including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
573
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sahasrabudhe D, Liesveld J, Minhajuddin M, Singh N, Nath S, Kumar V, et al.
Sci Rep
. 2024 Jun;
14(1):12868.
PMID: 38834690
Acute myeloid leukemia (AML) is fatal in the majority of adults. Identification of new therapeutic targets and their pharmacologic modulators are needed to improve outcomes. Previous studies had shown that...
2.
Ram J, Flamm G, Balys M, Sivagnanalingam U, Rothberg P, Iqbal A, et al.
Blood Adv
. 2018 Jan;
1(8):500-503.
PMID: 29296967
The persistence of a mutation at the time of complete remission warrants germ line analysis.Not all patients harboring germ line mutations have a family history of AML.
3.
Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, et al.
Cell Stem Cell
. 2016 Jul;
19(1):23-37.
PMID: 27374788
Adipose tissue (AT) has previously been identified as an extra-medullary reservoir for normal hematopoietic stem cells (HSCs) and may promote tumor development. Here, we show that a subpopulation of leukemic...
4.
Sivagnanalingam U, Balys M, Eberhardt A, Wang N, Myers J, Ashton J, et al.
PLoS One
. 2015 Jul;
10(7):e0132375.
PMID: 26177509
Cytogenetically normal acute myeloid leukemia (CN-AML) patients harboring RUNX1 mutations have a dismal prognosis with anthracycline/cytarabine-based chemotherapy. We aimed to develop an in vivo model of RUNX1-mutated, CN-AML in which...
5.
Guzman M, Yang N, Sharma K, Balys M, Corbett C, Jordan C, et al.
Mol Cancer Ther
. 2014 Jun;
13(8):1979-90.
PMID: 24934933
Most patients with acute myelogenous leukemia (AML) relapse and die of their disease. Increasing evidence indicates that AML relapse is driven by the inability to eradicate leukemia stem cells (LSC)....
6.
Pei S, Minhajuddin M, Callahan K, Balys M, Ashton J, Neering S, et al.
J Biol Chem
. 2013 Oct;
288(47):33542-33558.
PMID: 24089526
The development of strategies to eradicate primary human acute myelogenous leukemia (AML) cells is a major challenge to the leukemia research field. In particular, primitive leukemia cells, often termed leukemia...
7.
Ashton J, Balys M, Neering S, Hassane D, Cowley G, Root D, et al.
Cell Stem Cell
. 2012 Aug;
11(3):359-72.
PMID: 22863534
Leukemia stem cells (LSCs) represent a biologically distinct subpopulation of myeloid leukemias, with reduced cell cycle activity and increased resistance to therapeutic challenge. To better characterize key properties of LSCs,...
8.
Emo J, Meednu N, Chapman T, Rezaee F, Balys M, Randall T, et al.
J Immunol
. 2012 Mar;
188(8):3784-90.
PMID: 22427635
Negative regulation of innate immune responses is essential to prevent excess inflammation and tissue injury and promote homeostasis. Lysophosphatidic acid (LPA) is a pleiotropic lipid that regulates cell growth, migration,...
9.
Hassane D, Sen S, Minhajuddin M, Rossi R, Corbett C, Balys M, et al.
Blood
. 2010 Oct;
116(26):5983-90.
PMID: 20889920
We have previously shown that the plant-derived compound parthenolide (PTL) can impair the survival and leukemogenic activity of primary human acute myeloid leukemia (AML) stem cells. However, despite the activity...
10.
Weiss B, Stern S, Cox C, Balys M
Neurotoxicology
. 2005 Jun;
26(4):675-90.
PMID: 15970329
This project was undertaken to more completely understand the consequences of lifetime exposure to methylmercury. A series of experiments examined how perinatal or lifetime exposure to methylmercury affected behavioral performances...